...Sheng-Chu Chi; Chang-Chi Weng; Shih-Jen Chen; Tai-Chi Lin; Yu-Bai Chou; De-Kuang Hwang Introduction: Anti-vascular endothelial growth factor (VEGF) treatment stands as the primary approach for neovascular age-related macular degeneration (nAMD). Faricimab has recently emerged as a novel anti-VEGF...

... translocation, retinal pigment epithelium patch repair, SRH drainage, intravitreal injection of recombinant-tissue plasminogen activator (tPA), expansile gas and air displacement, and anti-vascular endothelial growth factor (anti-VEGF) injections. Nonsurgical therapeutical approaches include intravitreal anti...

...Andrew Mihalache; Amin Hatamnejad; Nikhil S. Patil; Marko M. Popovic; Rajeev H. Muni; Peter J. Kertes; David T. Wong Introduction: There are no guidelines on the optimal anti-vascular endothelial growth factor (anti-VEGF) monotherapy regimen for patients with polypoidal choroidal vasculopathy (PCV...

... treated diabetic macular edema (DME) patients. Methods: A multicenter, retrospective study of DME patients, previously treated with anti-VEGF injections, who were followed up during COVID-19 pandemic (2020) compared to pre-CO­VID-19 period (2019). Results: A total of 634 DME patients with a mean age...

... vascular progression and final vascularization in anti-VEGF treated eyes can be conducted using 3 methods [ 15, 23, 27 ]. The first is the ratio of retinal vascularization to the DD, the second is the ratio of retinal vascularization to the FD, and the third is the ratio of the avascular retina distance...

... implant (DEXi), after an initial poor response to anti-VEGF. Methods: The study involved a case series. Results: Twenty-three eyes of 17 patients were included. All were poorly responsive to anti-VEGF and switched to a DEXi after a mean of 12 anti-VEGF injections. The mean best-corrected visual acuity...

...Ramin Tadayoni; Laura Sararols; Georges Weissgerber; Rohini Verma; Andreas Clemens; Frank G. Holz Background: Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular...

... efficacy of anti-VEGF drugs using the Imaculaweb registry. Methods: In this observational study based on the Imaculaweb registry, outcome measures were the number of injections, the change in mean visual acuity (VA) and central macular thickness (CMT), and the time between diagnosis and the first injection...

...Jordi Monés; Rishi P. Singh; Francesco Bandello; Eric Souied; Xin Liu; Richard Gale Purpose: To assess the gap between visual acuity (VA) outcomes with anti-vascular endothelial growth factor (anti-VEGF) therapies in clinical trials and real-world practice, and explore the reasons for this gap...

...) when compared to the aCNV ( n = 32) and sCNV ( n = 11) subgroups. Qualitative criteria were inversely associated with the number of previous anti-VEGF injections (each p < 0.03), while quantitative metrics also suggested lower values. Conclusions: These findings suggest that OCTA may be supportive...

... of prematurity. Methods: In this study, patients were followed by two sequential fluorescein angiography (FA) examinations (Ret-Cam III Imaging System Clarity Medical Systems, Pleasanton, CA, USA) after anti-VEGF monotherapy. RVDB was determined by the ratio between DB (the distance from the center of the disk...

...Kimberly Spooner; Thomas Hong; Samantha Fraser-Bell; Andrew A. Chang Purpose: The current body of evidence on the efficacy and safety of anti-VEGFs for macular oedema secondary to branch retinal vein occlusion (BRVO) is steadily growing as large clinical trials and observational studies...

... in BCVA of +5.8 ± 7.4 letters (paired t test: p < 0.0001) and a significant decrease in mean CRT of –117 ± 134 µm (paired t test: p < 0.0001). The mean number of anti-VEGF injections was 10.0 ± 1.6 (range 6–12). The mean maximum interval between injections was 8.5 ± 2.9 weeks (range 4–14...

... stage ( p = 0.02), which was more evident in the earlier stages. Improvement was also greater for treatment-naïve patients ( p = 0.03). The posttreatment improvement in BCVA was strongly correlated with hot spot occlusion ( p < 0.001). Conclusions: Single-dose modified anti-VEGF treatment...

..., quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. 2017 Vitrectom&#x00ED;a Edema macular diab&#x00E9;tico Anti-VEGF...

... advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Anti-VEGF Bevacizumab Ranibizumab...

... until T45 when there was no longer a difference between the two subgroups. Fig. 3 Pressure profiles related to lens status. Fig. 3. Pressure profiles related to lens status. The IOP spike after IVI of anti-VEGF is systematically short in duration, as reported in various studies [ 1,2...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Vitrectomy Diabetic macular edema Anti-VEGF Visual acuity Optical coherence tomography Diabetic macular edema (DME) is a leading cause of decreased vision...

... or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Pigment epithelial detachment Spectral domain optical coherence tomography Atrophy Retina Anti-VEGF Intravitreal injections Age-related macular degeneration (AMD...

... to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Age-related macular degeneration Anti-VEGF Photodynamic therapy Choroidal neovascularization (CNV) due to age-related macular degeneration (AMD) is a frequent cause...